Hi-Risk/Recurrent/Advanced PrCa Video Chat, July 7, 2025
Hi-Risk/Recurrent/Advanced PrCa Video Chat, July 7, 2025
RECORD SETTER – 58 GENTS
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Novartis, Johnson and Johnson, Myriad Genetics, Telix, Blue Earth Diagnostics and Foundation Medicine
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Picks: Small cell morphing comes up twice in record setting group.(rd)
Topics Discussed
Hawaiian denovo Nx man finds Mack Roach; is the cancer morphing into small cell?; meta-study on early chemo not relevant if high PSA on Dx ; nevermind repeat PSMA – how about a PSA test?; another post-Pluvicto Gent whose cancer appears to morph; intraductal man is offered focal therapy – hello??; treatment success; UCSD team thinks suspicious local/distant Mx bogus – proceeds with simple RT; recurrence in Canada always poses treatment problems; zoledronic acid (Zometa) or denosumab (Xgeva) derivatives for osteoporosis?; does HT with salvage RT require abi?; Kwon’s doublet upgraded to triplet; what’s wrong with SoC options for man offered trials; another Mayo man needs GU MO Heath before proceeding.
Jeff Marchi – San Francisco sent: 6:29 PM Neuroendocrine trials From: MSKCC TargetDonc onclive ascopubs There are several ongoing clinical studies targeting DLL3 in neuroendocrine prostate cancer (NEPC): • Memorial Sloan Kettering Cancer Center (MSK) is opening a clinical trial testing a radioactive ligand that targets DLL3 in people with metastatic NEPC. Patients will first be screened for DLL3 expression and, if eligible, will receive the targeted therapy. • The SKYBRIDGE trial (NCT05652686) is a phase 1/2 study evaluating peluntamig (PT217), which targets DLL3 and CD47, in patients with DLL3-expressing neuroendocrine carcinomas, including NEPC. • A phase 1b study of tarlatamab, a DLL3-targeted bispecific T-cell engager, is ongoing in patients with metastatic NEPC, showing manageable safety and encouraging anti-tumor activity in DLL3-positive cases (NCT04702737). • Other agents like HPN328, another DLL3-targeted T-cell engager, are also being tested in neuroendocrine prostate cancer. These studies reflect a strong research focus on DLL3 as a therapeutic target for NEPC.
Alain sent: 7:16 PM Thanks guys, see you next time!
Doug D sent: 7:18 PM Thanks all. See you next time.
Wes – San Diego sent: 7:19 PM To all. Your great advice over the past 6 months helped me immensely in finding and getting great care, and a treatment plan that matched my goals.
George (Chicago) sent: 7:27 PM Thank you, gentlemen. Very helpful.
Bob Schwartz, USN, Venice FL sent: 7:35 PM Good mtg., got to go.
Thomas M sent: 7:37 PM Thank you all for your help. Thomas.
Jon McPhee Toronto sent: 7:37 PM Thanks. Goodnight.
Steve White sent: 7:44 PM Thanks so much for your help tonight. Goodnight.
Hi-Risk/Recurrent/Advanced PrCa Video Chat, June 16, 2025
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Novartis, Johnson and Johnson, Myriad Genetics, Telix, Blue Earth Diagnostics and Foundation Medicine
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: After 20 years continuously on AS, 3+3 becomes metastatic (rd)
Topics Discussed
After 20 years continuously on AS, 3+3 becomes metastatic; man with recurrence must learn to be his own best advocate; denovo Mx Alaskan needs better treatment fromf the VA; success report from PBRT; trust Dr. Zhao!; primary treatment with BPH; long term management of recurrent, oligo-MX disease; abo vs daro; infections and A-fib defer PrCa Tx.; scans show clean but HT causes sweats and fatigue; youngr Gent shows nothing on PSMA at 0.14 – needs to switch his care; HT is doing its job
Chat Log
steve cavill – Melbourne, Australia sent: 5:32 PM what pirads? That gives a good idea of grade hmm ok, biopsy would be useful !
Bob Alvord sent: 6:02 PM I download all my scans, biopsy reports and labs to Chat Gtp. Chat returns detailed interpretations after I also mention that I am not a doctor, so in plain language. I also ask Chat for relevant questions. Not a perfect way but a good way to generate questions.
Jim Marshall, Alexandria, VA sent: 6:08 PM Veterans Support Group, Tuesday at 2000ET.
Jim Marshall, Alexandria, VA sent: 6:35 PM If one takes FINASTERIDE it will artifically drop the PSA by 50%.
Russ – PCaWarrior sent: 6:50 PM NCCN Low/favorable IR: SBRT alone is acceptable; ADT is optional. Unfavorable IR: SBRT + 4–6 months ADT is recommended. High risk: SBRT + 2–3 years ADT (Category 2A). Very high risk: SBRT only in trial settings; standard is EBRT ± brachytherapy + long‑term ADT. Finasteride : PSA. Finasteride blocks 5AR type 2. That is the predominant type in the prostate and PCa cells. DHT drops. PSA drops. Androgens (e.g. T) upgregulate PSA. ARSIs (e.g. Xtandi) downregulate it. Practical solution to upregulating or downregulating is to measure PSA in the same environment.
Jim Marshall, Alexandria, VA sent: 6:56 PM Was on Eligard + ABI for 5 years and NO SWEAT with side effects and now 3 years into Treatment Holiday and counting.. Mitigated ADT + ABI with exercise every day and diet.
Richard – Virginia sent: 7:04 PM i have to leave. I will talk next week.
dan, alexandria sent: 7:06 PM Thanks all… I have to leave.
Ben Nathanson sent: 7:36 PM John G –The first of these doesn’t seem to cite any sources, meaning none of the claims can be verified by readers. I distrust that. The second is in the context of chemotherapy, and is also retrospective — not clear it’s relevant to your case. Also fwiw the work was funded by Bayer, the maker of daro.
Hi-Risk/Recurrent/Advanced PrCa Video Chat, June 2, 2025
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime!
Editor’s Pick: Saving the best news ’til almost last – AnCan’s own walking miracle who postponed his funeral! (rd)
Topics Discussed
Community care MO is sadly clueless; more community care but GU MO available; 3rd BCR brings up trial that smacks of Academic Conflict of Interest; exhausted after 3rd Pluvicto but hisLu177 peers say hang in; more scans and bone Bx negative, but MGUS appears; perfect timing for mHSPC man wanting daro – Nubeqa approved for mHSPC ; surgery vs RT decision for high risk man who also faces academic CoI; starting Firmagon; Tumor Board dismissed for GU MO – as AnCan predicted; simple PSA test may allieve concern over lower back pain; Gent with too many mets to count NED post 6x Pluvicto; PSA remains stable with no treatment
Chat – abbreviated this week for space!
Alfredo in Houston sent: 5:20 PM I lived in East Sacramento for 20 years.
Bob Alvord sent: 5:55 PM Thank you for the information on doctors in UC
Russ – PCaWarrior sent: 6:28 PM 6. Myokine/Metastatic PCa Trial • Population: Men with mCRPC • Intervention: 6 months supervised aerobic + resistance exercise vs. self-directed exercise • Findings: • Higher serum myokine levels in supervised group • Post-exercise serum from exercisers inhibited DU145 PCa cell growth in vitro • Conclusion: Exercise may promote systemic adaptations that suppress tumor growth in mCRPC.
Matt sent: 6:37 PM Hi guys. heading out. have a great week. hope to see some of you thursday…..
Russ – PCaWarrior sent: 6:38 PM As of mid-2025, darolutamide (Nubeqa) has received **regulatory approval for use in metastatic hormone-sensitive prostate cancer (mHSPC) ** before chemotherapy, based on strong outcomes from the ARASENS trial. Here’s a summary of current approvals and guidance:
Steven T sent: 6:55 PM Thanks everyone for your input!
Russ – PCaWarrior sent: 6:55 PM I did RP. Is this primary? First line? I was biopsied 3+4. Turned out very different 4+5. If I had done RT I would have never known. 30% approx biopsies are incrorrectly graded. I forget the breakdown. Something like 18% downgrades and 12% upgrades. Many studies.
Alfredo in Houston sent: 7:01 PM Family is calling for me, so I must bid y’all a good night. Best wishes to all.
Peter M sent: 7:03 PM Good night gents. Great meeting!
Bob Alvord sent: 7:05 PM Thank you all so much! Like the terminator, “I’ll be back!”
Russ – PCaWarrior sent: 7:06 PM Nite Bob. One of my favorite movies.
Bob Alvord sent: 7:06 PM MIne too!
Michael in Denver sent: 7:07 PM Thanks. Good nite.
Bob Alvord sent: 7:07 PM Nite All. Thanks you!
John A sent: 7:07 PM goodnight gentlemen
dan, alexandri sent: 7:09 PM Night Gents… thanks for updates.
Thomas M sent: 7:14 PM Got to skoot. Thanks all for a very informative meeting. Peace.
RJ Smith (Seattle)sent: 7:28 PM NTD–Great News Frank!
Non-Conspiratorial Questions around the Biden diagnosis?
One of the things AnCan does best is ask questions. We ask them of you, and we suggest you ask them of others. We do that to make you your own best advocate, and we do it to represent our constituency and keep others honest. We do not do it, by and large, to make political waves although I have been known to voice my deep displeasure and distrust of the current Administration and its Leader.
When I, on behalf of AnCan, raised significant questions around Joe Biden’s diagnosis of metastatic hormone sensitive prostate cancer (mHSPC), it was to make it clear that rarely does this arise out of the blue unless someone has been sleeping on the switch. I stated it smelled fishy and there had to be more to disclose. Sure enough,there was.
As one of the first to question, it was reassuring to see the legitimate press, including the Washington Press and the New York Times, asked very similar questions and quoted highly recognized experts, who posed the same questions.
Several articles also interviewed inappropriate subjects. Urologists who should not be treating advanced prostate cancer, medical oncologists who don’t treat prostate cancer, and worst of all blow hard doctors with blood on their hands.
The NYT’s choice of Hopkins Professor Otis Brawley is the most notable offender. Dr. Brawley, a 66-yr old African American, boasts that he has never tested his own PSA. During his time as Chief Medical Ofice at American Cancer Society, Brawley stopped all patient suport for our disease, and spearheaded efforts to stop PSA screening. He was the driving force behind the USPSTF recommendations not to screen. I place the 35% increase in prostate cancer specific deaths over the past 10 years squarely at his feet.
What are some of these important questions? Why wasn’t Joe Biden screened after 2013? Don’t even raise the fact that he turned 70 and the ‘Guidelines’ don’t require it. #1 – they are just guidelines as Dr. Peter Carroll pointed out in his interview with The Active Surveillor, AnCan Advisory Boardie, Howard Wolinsky. #2, continued screening to at least 75 is recommended if risk factors are present. It’s reported that Biden did have risk factors including urinary issues, and a previous cancer that could have been related to prostate. And #3… he’s no ordinary Joe! As a holder of high elected office, Biden should be held to a higher standard.
By the way AnCan believes all men are entitled to a PSA test no matter their age. PSA testing is about information not treatment. Results and treatment are definitely subject to Shared Decision Making. Who was running Biden’s medical welfare as VP and President?
AnCan would hazard a guess the NIH or the Military (Walter Reade, Fort Belvoir) had a hand… or perhaps an index finger involved. We have our own experience of these facilities. Last time AnCan raised valid questions publicly about their care we were asked to back off. How long has Biden been in treatment – do we know it’s mHSPC? We hope it is but won’t know until he’s been in treatment for a while. Yet his Office tells us it is mHSPC. That gives us reason to ask if he’s been on treatment for a while and more is known. No conspiracy – a question based on public disclosures.President Biden’s poor executive function in his debate performance is very typical of men who have been on Androgen Deprivation Therapy (or more extensive hormone therapy) for a period of time. Yes – it could have been flu/covid/ cold; it could also have been MS or Parkinson’s; and it could have been HT now we know his diagnosis.
There are more questions, and there is probably more to come to light. What gave me pause for thought were the critics who came down on me and AnCan hard. We were accused of conspiracy theory and disrespect to the Bidens… just for asking these questions.
One more question… is this a malevolent sign of our times? People are too quick to assign political motive and divisive intent. It’s sad when enquiring and educated minds are lambasted for raising valid questions that deserve answers. AnCan, and I personally, wish the Bidens well. I have always supported and held him in regard. His disease progression may throw light on what was known on Friday, May 16 so keep an open mind. If anything is to come out of this, better screening guidelines for men over 70, and better supervision of Presidential health would be two good outcomes.
Also more focus on how an orange man of 77 with an intact prostate can possibly have a PSA of 0.10 – or is this just another lie the American public has to eat.
onward & upwards, rick davis, founder AnCan Foundation
Hi-Risk/Recurrent/Advanced PCa Video Chat, Aug 5, 2024
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostics.
If you missed any recent recordings, you’ll find a full list either on our YouTube Playlist (click above) or visit our Blog Post https://ancan.org/our-recent-blog-posts-in-case-you-missed-them/ Sign up for our Blog by checking the New Blog box at https://ancan.org/contact-us/
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime!
Editors Pick: Crazy increases in PSA suggests therapy is not working; Dr. Bob GRHS (rd)
Topics Discussed
Dr. Bob GRHS’; low level mCRPC – what next?; fermented foods; starting olaparib with somatic BRCA2; chemo holiday for our foamy gland man; long resistant gent starts mono or double HT in the Fall; Vit D and Metformin discussion; heart is solid – PSMA to follow; erratic, fluctuating PSA suggests Tx not working – needs 2nd opinion; Decipher not useful for this situation; stopped abi and prednisone on his schedule + psych issues; 2 gents start start HT for 1st time; Intermittent HT discussion; restarting mono LHRH.
HAHA. Yes. That’s exactly what I was thinking. But yes. The older crowd. I really want to make the under 60 zoom Thursday but I’ll be playing taxi cab during that time. Sigh.
CALCIUM SCORE PRESENCE of CAD (coronary artery disease) O No sign of CAD 1-10 Minimal signs of CAD 11-100 Mild signs of CAD 101-400 Moderate signs of CAD 401+ Extensive signs of CAD
Frank Fabish Columbus OH
sent: 8:33 PM
Thanks for listening guys. Got to run. thanks for the dialogue.
Michael McCabe
sent: 8:42 PM
Got to go guys, see everyone at next meeting
Steve Roux, MI
sent: 8:43 PM
GREAT Meeting guys – I need to take my rescue puppy out for a walk. Goodnight all!
THOMAS M
sent: 8:52 PM
I have used the “Cancer Care” booklet from the FLCCC Alliance, Dr. Paul Marik, MD. The discussion about vitamin D brought this to mind. It suggests repurposed uses of various supplements and pharmaceuticals for cancer treatment. Its worth a glance.
Gary P
sent: 8:55 PM
https://betterdayscounselingllc.com/
John A
sent: 9:10 PM
gotta stop now guys see you next week
Matt M
sent: 9:12 PM
gotta go boys, have a great week! I’ll be on some next onens…..
THOMAS M
sent: 9:22 PM
Time to scoot. Thanks all.
Dr. Jeff
sent: 9:39 PM
gotta sign off. Past my bedtime. see everyone next week
